公开(公告)号：US20210130305A1

公开(公告)日：2021-05-06

申请号：US16935531

申请日：2020-07-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Keisuke HIRAI ,  Takashi ISHIKAWA

IPC: C07D263/52 ,  A61K31/428 ,  A61K31/423 ,  A61P25/00 ,  C07D277/60 ,  C07D413/06

Abstract: The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20210115048A1

公开(公告)日：2021-04-22

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji KITAMURA ,  Zenichi IKEDA ,  Minoru IKOMA ,  Koji WATANABE ,  Hideki HIROSE ,  Takafumi YUKAWA ,  Sachie MORIMOTO ,  Naoki NISHIZAWA ,  Taiji ASAMI

IPC: C07D487/04 ,  A61P9/04 ,  A61K47/38 ,  A61K31/4184 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US20210115039A1

公开(公告)日：2021-04-22

申请号：US17131024

申请日：2020-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro IWATA ,  Yukihiro IKEDA

IPC: C07D471/04

Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.

公开(公告)号：US10980825B2

公开(公告)日：2021-04-20

申请号：US16185258

申请日：2018-11-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Yoshihisa Nakada ,  Michiyo Mochizuki

IPC: A61K31/7084 ,  A61K31/7076 ,  A61K47/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20210052600A1

公开(公告)日：2021-02-25

申请号：US16958394

申请日：2018-12-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Izumi Kamo ,  Nele MUELLER-PLOCK

IPC: A61K31/553 ,  A61K31/55 ,  A61P1/00 ,  A61P13/00

Abstract: The present invention provides a medicament for use in treating stress urinary incontinence with fewer adverse effects including a body weight lowering effect. The present invention also provides a medicament for use in treating a disease such as incontinence of feces and further provide a medicament for use in treating a disease such as incontinence of feces with fewer adverse effects including a body weight lowering effect.
A medicament for use in treating stress urinary incontinence, comprising a 5-HT2C receptor agonist, wherein the medicament is administered at a dosage lower than the minimum dosage of the agonist as an anti-obesity drug. A medicament for use in treating incontinence of feces, etc., comprising a 5-HT2C receptor agonist. A medicament for use in treating incontinence of feces, comprising a 5-HT2C receptor agonist, wherein the medicament is administered at a dosage lower than the minimum dosage of the agonist as an anti-obesity drug.

公开(公告)号：USRE48334E1

公开(公告)日：2020-12-01

申请号：US15445251

申请日：2017-02-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Junya Shirai ,  Hideyuki Sugiyama ,  Taku Kamei ,  Hironobu Maezaki

IPC: C07D401/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08

Abstract: The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R2, R3, R4a and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain; R1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

公开(公告)号：US10787462B2

公开(公告)日：2020-09-29

申请号：US15769201

申请日：2016-10-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takatoshi Yogo ,  Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Katoh ,  Tomohiro Seki ,  Yoshihisa Nakada

IPC: C07D519/00 ,  C07D487/04 ,  C07D471/04 ,  C07D513/04 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P31/12 ,  A61P13/12 ,  A61P1/16 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like.The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10786506B2

公开(公告)日：2020-09-29

申请号：US16065362

申请日：2016-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahisa Matsuda ,  Takashi Motoyaji ,  Shuji Kitamura ,  Masato Yoshida

IPC: A61K31/517 ,  A61K31/519 ,  A61P9/04

Abstract: The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

公开(公告)号：US10745397B2

公开(公告)日：2020-08-18

申请号：US15746828

申请日：2016-07-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Dinesh Barawkar ,  Anil M Deshpande ,  Santosh Patil ,  Yogesh Waman ,  Anil Panmand ,  Dilip Jadhav ,  Bheemashankar Kulkarni

IPC: C07D498/04 ,  C07D471/04 ,  C07D513/04 ,  A61P19/02

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

公开(公告)号：US20200255439A1

公开(公告)日：2020-08-13

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto KAMATA ,  Hideyuki SUGIYAMA ,  Minoru NAKAMURA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Tomohiro OKAWA ,  Hidekazu TOKUHARA

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.